To date, only one short-term phase 1 study has been performed on MS patients (NCT02760056, www.clinicaltrials.gov; accessed on 7 April 2023) [57] out of the numerous synthetic TRβ ligands developed [58]. The gene discussed is THRB; the disease is myeloid sarcoma.